Skip to content

Study · Animal study (in vivo) · 2018

10 results

Role of Teriparatide in Glucocorticoid-induced Osteoporosis through Regulating Cellular Reactive Oxygen Species.

Wang T, Han C, Tian P, Li PF, Ma XL

Orthopaedic surgery10 May 2018Cited by 21 (Europe PMC)

PMID29745033 (opens in a new tab)PMCIDPMC6594530 (opens in a new tab)DOI10.1111/os.12369 (opens in a new tab)PepBankPUB-29745033
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In a glucocorticoid-induced osteoporosis model, teriparatide reversed methylprednisolone-induced reduction in trabecular thickness.

    In plain wordsIn an animal osteoporosis model, teriparatide improved trabecular thickness compared with methylprednisolone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular thickness
    Study

    n: not reported in source

    Glucocorticoid-induced osteoporosis model
    Comparator
    Methylprednisolone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The microstructural parameters Tb.Th, BV/TV, and Tb.N in the methylprednisolone (MPS) group were markedly reduced compared with the control group, but additional treatment with teriparatide could remarkably reverse the methylprednisolone-induced reduction of these parameters.
    1 context sentence
    Summary · context
    A glucocorticoid-induced osteoporosis (GIOP) model was used to confirm the anti-ROS and anti-apoptosis ability of teriparatide.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In a glucocorticoid-induced osteoporosis model, teriparatide reversed methylprednisolone-induced reduction in bone volume fraction.

    In plain wordsIn an animal osteoporosis model, teriparatide improved bone volume fraction compared with methylprednisolone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular BV/TV
    Study

    n: not reported in source

    Glucocorticoid-induced osteoporosis model
    Comparator
    Methylprednisolone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The microstructural parameters Tb.Th, BV/TV, and Tb.N in the methylprednisolone (MPS) group were markedly reduced compared with the control group, but additional treatment with teriparatide could remarkably reverse the methylprednisolone-induced reduction of these parameters.
    1 context sentence
    Summary · context
    A glucocorticoid-induced osteoporosis (GIOP) model was used to confirm the anti-ROS and anti-apoptosis ability of teriparatide.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In a glucocorticoid-induced osteoporosis model, teriparatide reversed methylprednisolone-induced reduction in trabecular number.

    In plain wordsIn an animal osteoporosis model, teriparatide improved trabecular number compared with methylprednisolone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular number
    Study

    n: not reported in source

    Glucocorticoid-induced osteoporosis model
    Comparator
    Methylprednisolone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The microstructural parameters Tb.Th, BV/TV, and Tb.N in the methylprednisolone (MPS) group were markedly reduced compared with the control group, but additional treatment with teriparatide could remarkably reverse the methylprednisolone-induced reduction of these parameters.
    1 context sentence
    Summary · context
    A glucocorticoid-induced osteoporosis (GIOP) model was used to confirm the anti-ROS and anti-apoptosis ability of teriparatide.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In a glucocorticoid-induced osteoporosis model, teriparatide inhibited the methylprednisolone-induced increase in trabecular separation.

    In plain wordsIn an animal osteoporosis model, teriparatide reduced trabecular separation compared with methylprednisolone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular separation
    Study

    n: not reported in source

    Glucocorticoid-induced osteoporosis model
    Comparator
    Methylprednisolone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, the parameter Tb.Sp was significantly increased in the methylprednisolone group compared to the control group, and this increase could be inhibited by teriparatide.
    1 context sentence
    Summary · context
    A glucocorticoid-induced osteoporosis (GIOP) model was used to confirm the anti-ROS and anti-apoptosis ability of teriparatide.
  5. 05LabIn vitro (cells)Mechanism

    In MLO-Y4 cells, teriparatide restored proliferation inhibited by dexamethasone.

    In plain wordsIn cells, teriparatide improved proliferation compared with dexamethasone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocyte proliferation
    Study

    n: not reported in source

    MLO-Y4 osteocytes exposed to dexamethasone
    Comparator
    Dexamethasone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The CCK-8 assay revealed that Dex reduced the proliferative capability of cells significantly, whereas incubation with teriparatide resulted in a remarkable increase in the proliferation of osteocytes.
    3 context sentences
    Summary · context
    In addition, teriparatide can rescue the effect of inhibiting cell proliferation due to Dex treatment.
    Summary · context
    We performed the DCFH-DA assay to investigate the role of ROS in MLO-Y4 cells caused by dexamethasone (Dex).
    Summary · context
    Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose).
  6. 06LabIn vitro (cells)Mechanism

    In MLO-Y4 cells, teriparatide reduced reactive oxygen species versus dexamethasone alone.

    In plain wordsIn cells, teriparatide reduced reactive oxygen species compared with dexamethasone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseReactive oxygen species
    Study

    n: not reported in source

    MLO-Y4 osteocytes exposed to dexamethasone
    Comparator
    Dexamethasone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the Dex+Teriparatide group showed less ROS when compared with the Dex group.
    2 context sentences
    Summary · context
    We performed the DCFH-DA assay to investigate the role of ROS in MLO-Y4 cells caused by dexamethasone (Dex).
    Summary · context
    Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose).
  7. 07LabIn vitro (cells)Mechanism

    In MLO-Y4 cells, teriparatide reduced caspase-3 versus dexamethasone alone.

    In plain wordsIn cells, teriparatide reduced caspase-3 compared with dexamethasone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCaspase-3 versus dexamethasone
    Study

    n: not reported in source

    MLO-Y4 osteocytes exposed to dexamethasone
    Comparator
    Dexamethasone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to the Dex group, incubation with teriparatide resulted in a significant decrease in caspase-3 level;
    2 context sentences
    Summary · context
    We performed the DCFH-DA assay to investigate the role of ROS in MLO-Y4 cells caused by dexamethasone (Dex).
    Summary · context
    Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose).
  8. 08LabIn vitro (cells)Mechanism

    In MLO-Y4 cells, teriparatide increased AKT expression versus dexamethasone alone.

    In plain wordsIn cells, teriparatide increased AKT compared with dexamethasone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAKT expression
    Study

    n: not reported in source

    MLO-Y4 osteocytes exposed to dexamethasone
    Comparator
    Dexamethasone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results of immunofluorescence also showed that Akt was highly expressed in the teriparatide group when compared with the Dex group.
    2 context sentences
    Summary · context
    We performed the DCFH-DA assay to investigate the role of ROS in MLO-Y4 cells caused by dexamethasone (Dex).
    Summary · context
    Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose).
  9. 09LabIn vitro (cells)Mechanism

    In MLO-Y4 cells, teriparatide rescued dexamethasone-induced apoptosis.

    In plain wordsIn cells, teriparatide reduced cell death compared with dexamethasone alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseApoptosis
    Study

    n: not reported in source

    MLO-Y4 osteocytes exposed to dexamethasone
    Comparator
    Dexamethasone alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, teriparatide promotes the expression of AKT, and rescues the apoptosis effect caused by Dex.
    2 context sentences
    Summary · context
    We performed the DCFH-DA assay to investigate the role of ROS in MLO-Y4 cells caused by dexamethasone (Dex).
    Summary · context
    Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose).

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 10LabNot a test of Teriparatide (PTH 1-34) aloneIn vitro (cells)Mechanism

    In dexamethasone-exposed MLO-Y4 cells, caspase-3 with teriparatide did not differ significantly from untreated controls.

    In plain wordsIn cells exposed to dexamethasone, caspase-3 with teriparatide did not differ significantly from untreated controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCaspase-3 versus untreated control
    Study

    n: not reported in source

    MLO-Y4 osteocytes exposed to dexamethasone
    Comparator
    Untreated control
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    when compared with the control group, the caspase-3 level was not significantly different, indicating that teriparatide can rescue apoptosis during Dex exposure.
    2 context sentences
    Summary · context
    We performed the DCFH-DA assay to investigate the role of ROS in MLO-Y4 cells caused by dexamethasone (Dex).
    Summary · context
    Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.